Evaluation of the impact of writing exercises interventions on quality of life in patients with psoriasis undergoing systemic treatments

British Journal of Dermatology

Volumn 167, Issue 6, 2012, Pages 1254-1264

  Tabolli, S ^a   Naldi, L ^b   Pagliarello, C ^a   Sampogna, F ^a   Di Pietro, C ^a   Spagnoli, A ^a   Abeni, D ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b Centro Studi GISED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; WRITING;

ADULT; EDUCATIONAL STATUS; EMOTIONS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SOCIAL CLASS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; WRITING;

EID: 84870249448     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11147.x     Document Type: Article

References (43)

1. Sampogna F, Gisondi P, Melchi CF, et al. Multipurpose psoriasis research on vital experiences investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-9.
2. Sampogna F, Sera F, Abeni D, and the IMPROVE investigators. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122: 602-7.
3. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004; 9: 136-9.
4. Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45: 72-6.
5. Choi J, Koo JY,. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49: S57-61.
6. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
7. Sampogna F, Chren MM, Melchi CF, et al. Age, gender, quality of life, and psychological distress in patients with psoriasis. Br J Dermatol 2006; 154: 325-31.
8. Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006; 154: 844-9.
9. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
10. Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52: 434-44.
11. Picardi A, Abeni D, Renzi C, et al. Increased psychiatric morbidity in female outpatients with skin lesions on visible parts of the body. Acta Derm Venereol 2001; 81: 410-14.
12. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-7.
13. Sampogna F, Picardi A, Chren MM, et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 2004; 66: 620-4.
14. Molitor P, Seibt G,. Psychosomatic aspects of psoriasis: affectivity and conflict. Z Psychosom Med Psychoanal 1984; 30: 247-69.
15. Duran V, JovanoviÄ M, MisiÄ-Pavkov G, et al. The effect of stress and personality structure on the onset and severity of the clinical picture of psoriasis. Med Pregl 1993; 46: 120-3.
16. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A,. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000; 14: 241-2.
17. Rubino IA, Sonnino A, Stefanato CM, et al. Separation-individuation, aggression and alexithymia in psoriasis. Acta Derm Venereol Suppl (Stockh) 1989; 146: 87-90.
18. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993; 50: 681-9.
19. Spiegel D, Bloom J, Kraemer H, Gottheil E,. Effects of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989; 2: 888-91.
20. Vedhara K, Morris RM, Booth R, et al. Changes in mood predict disease activity and quality of life in patients with psoriasis following emotional disclosure. J Psychosom Res 2007; 62: 611-19.
21. Paradisi A, Abeni D, Finore E, et al. Effect of written emotional disclosure interventions in persons with psoriasis undergoing narrow band ultraviolet B phototherapy. Eur J Dermatol 2010; 20: 599-605.
22. Moses LE, Oakford RY,. Tables of Random Permutation. Stanford, CA: Stanford University Press, 1963.
23. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
24. Apolone G, Mosconi P,. Questionario Sullo Stato di Salute. Milan: Guerini e associati, 2000.
25. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ,. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-40.
26. Abeni D, Picardi A, Pasquini P, et al. Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2242 dermatological outpatients. Dermatology 2002; 204: 43-9.
27. Piccinelli M, Bisoffi G, Bon MG, et al. Validity and test-retest reliability of the Italian version of the 12-item General Health Questionnaire in general practice: a comparison between three scoring methods. Compr Psychiatry 1993; 34: 198-205.
28. Picardi A, Abeni D, Pasquini P,. Assessing psychological distress in patients with skin diseases: reliability, validity and factor structure of the GHQ-12. J Eur Acad Dermatol Venereol 2001; 15: 410-17.
29. Picardi A, Abeni D, Mazzotti E, et al. Screening for psychiatric disorders in patients with skin diseases: a performance study of the 12-item General Health Questionnaire (GHQ-12). J Psychosom Res 2004; 57: 219-23.
30. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-66.
31. Lang KY, Zeger SL,. Longitudinal analysis using generalized linear models. Biometrika 1986; 73: 13-22.
32. Ullrich PM, Lutgendorf SK,. Journaling about stressful events: effects of cognitive processing and emotional expression. Ann Behav Med 2002; 24: 244-50.
33. Cameron LD, Nicholls G,. Expression of stressful experiences through writing: effects of self-regulation manipulation for pessimists and optimists. Health Psychol 1998; 17: 84-92.
34. Klein K, Boals A,. Expressive writing can increase working memory capacity. J Exp Psychol Gen 2001; 130: 520-33.
35. Smyth JM, Stone AA, Hurewitz A, Kaell A,. Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis. JAMA 1999; 281: 1304-9.
36. Kelly JE, Lumley MA, Leisen ICC,. Health effects of emotional disclosure in rheumatoid arthritis patients. Health Psychol 1997; 16: 331-40.
37. Smyth JM,. Written emotional expression: effect sizes, outcome type, and moderating variables. J Consult Clin Psychol 1998; 66: 174-84.
38. Petrie KJ, Fontanilla I, Thomas MG, et al. Effect of written emotional expression on immune function in patients with human immunodeficiency virus infection: a randomized trial. Psychosomat Med 2004; 66: 272-5.
39. Stanton AL, Danoff-Burg S, Sworowski LA, et al. Randomized, controlled trial of written emotional expression and benefit finding in breast cancer patients. J Clin Oncol 2002; 20: 4160-8.
40. Pennebaker JW,. Writing about emotional experience as a therapeutic process. Psychol Sci 1997; 8: 162-6.
41. Pennebaker JW, Kiecolt-Gaser JK, Glaser R,. Disclosure of traumas and immune function: health implications for psychotherapy. J Consult Clin Psychol 1988; 56: 239-45.
42. Petrie KJ, Booth RJ, Pennebaker JW, et al. Disclosure of trauma and immune response to hepatitis B vaccination program. J Consult Clin Psychol 1995; 63: 787-92.
43. Wetherell M, Byrne-Davis L, Dippe P, et al. The effects of emotional disclosure on psychological and physiological outcomes in patients with rheumatoid arthritis: an exploratory home-based study. J Health Psychol 2005; 10: 277-85.